URGN

URGN

Last Updated:

Q3'20

UroGen Pharma

UroGen Pharma is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases.

Cash

$119.6M

Burn Rate (Qtr)

-$28.8M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

JELMYTO® (mitomycin)

Low-grade upper tract urothelial carcinoma (UTUC)

Quarterly Sales (Approved)

March 5, 2021 (Est)

UGN-102

Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 (Enrollment)

Year End 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

URGN - Complete & Durable Resp...

Summary: 65% Complete Response Rate at Three Months Duration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method; Median Duration of Response...

URGN - Centers for Medicare & ...

#URGN "announced that the Centers for Medicare & Medicaid Services (CMS) has established a permanent and product-specific J-code for Jelmyto® (mitomycin) for pyelocalyceal solution that will take effe...

URGN - UroGen Pharma Reports T...

Summary: Top-line Results from UGN-102 OPTIMA II Phase 2b Trial Expected by Year End 2020; On Track to Initiate Phase 3 ATLAS Trial by Year End Achieved Jelmyto® Net Product Revenue of $3.5 Million i...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon